Hyperglycemia, PostprandialNCT05152745
Effect of Ginger Extract on Postprandial Glycaemia of Healthy Adults and Its Antioxidant Properties
A study testing Ginger aqueous extract in people with Hyperglycemia, Postprandial, run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.
Trial summary
Background: Hyperglycemia is a risk factor to disease development, namely, diabetes mellitus. The blood glucose level management, particularly on post-prandial period has an important role in the prevention of different diseases. Ginger is a specie that has been demonstrated a benefit effect on glycaemia on diabetes. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Hyperglycemia, Postprandial
- What is being tested?
- Ginger aqueous extract
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 sitePortugal
- Study dates
- 5 May 2017to 30 Oct 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- subjects without glucose metabolism alteration
Who cannot join
- medication for glycemia
- had gastrointestinal symptoms or disease
- pregnancy or lactation
- had allergy to ginger.
- to ingest ginger at the day before the intervention.
Trial locations and contacts
1 site in 1 country.
Portugal1 site
Instituto Universitário Egas Moniz
Almada, Monte de Caparica, 2829-511
About this study
Official title: Effect of Ginger Extract on Postprandial Glycemia of Healthy Adults and Its Antioxidant Properties: a Randomized Controlled Trial
Background: Hyperglycemia is a risk factor to disease development, namely, diabetes mellitus. The blood glucose level management, particularly on post-prandial period has an important role in the prevention of different diseases. Ginger is a specie that has been demonstrated a benefit effect on glycaemia on diabetes.
Aim: The aim of this study was 1) to investigate the effects of ginger infusion in the glycaemic response in nondiabetic adults; 2) to evaluate total phenolic content the antioxidant activity of Ginger (Zingiber officinale Roscoe) aqueous extracts.
Methodology: 24 nondiabetic subjects were randomly allocated into two groups: intervention group (GI; n=15) and control group (GC; n=15). An oral glucose solution (OGTT) and an OGTT following ginger extract solution were administrated in control and intervention groups, respectively. Blood glucose levels were measurement at fasting and after 30, 60, 90 and 120 minutes after interventions in both groups. Total phenolic content and flavonoids compounds determination of the aqueous ginger extract was determined according to Prabha method. Antioxidant activity was also measured through ABTS method and free radicals inhibition capacity. Repeated Measures ANOVA of mixed type and independent samples t-test were used in statistical analysis.
Read the detailed description
This clinical trial was approved by Ethical Committee (process number 519 at 23 November 2016). All participants signed a written informed consent after aim and experimental risk procedures explanation and its protected confidentiality was guaranteed. The experimental procedure involving human was care out according Declaration of Helsinki.
This blind (to participants) randomized controlled clinical trial was conducted at Egas Moniz higher education school in 30 nondiabetic adults. Participants with ages between 18 and 40 were selected and randomly allocated in intervention group (IG) (n=15) and control group (CG) (n=15), in which participants were alternated include in the groups. The IG performed an oral glucose tolerance test (OGTT) followed by aqueous ginger extract administration and the CG performed an OGTT administration alone.
For ginger extract preparation, powder ginger (Zingibre officinalle Roscoe) was obtained from Portugal Company with India origin and stored in a dried environmental locally until needed. The product has a batch number of LI1GIGRNT150012. Powder ginger was individually weight (0.2g each dose) and added to 100mL of boiled water obtaining the ginger extract, infusing 10 minutes. Ginger extract solution was after cooled at room temperature and distributed to each participant. This method was adapted by Wilkinson, J. M. (2000). For chemical analysis, a aqueous ginger extract previously obtained was used.
Regarding to blood glucose level assessment, the blood sample were collected for each participant using a capillary drop blood before the intervention (fasting) and after 30, 60, 90 and 120 minutes. The blood glucose level analysis was performed using a strips for glucose meter (Onetouch Select Plus Flex), a sterilized lancet and a glucose meter equipment.
General characteristics data of the participants were collected, namely, anthropometrics data, pharmacologic treatment and medical condition using a questionnaire. In addition, a 24-hour dietary recall at the day before the intervention was employing to sample participants. The nutritional analyzed of diet ingested was performed by Food Processor SQL (version 10.5.0).
The total phenolic compounds determination of the aqueous ginger extract was determined according to Folin-Ciocalteu method. The total phenolic results were expressed as mg gallic acid equivalent (GAE)/L of ginger extract. A volume of 125 μL of ginger extract and 2 mL of sodium carbonate were added to 2.5 mL of Folin-Ciocalteu reagent. After 15 min the absorbance was measured at 765 nm. The flavonoids compounds determination of the aqueous ginger extract was determined according to Prabha method. The flavonoids results were expressed as mg quercetin equivalent (GAE)/L of ginger extract. A volume of 2 mL of ginger extract were added to 0.1 mL of aluminum chloride anhydrous solution (10%), 0.1 mL of potassium acetate (1M) and 2.8 mL of distilled water. After 30 min the absorbance was measured at 415 nm.
The antioxidant activity was measured through different assays:
The superoxide anion radicals scavenging activity was determined based on Morais et al method. Superoxide anion was generated by reacting phenazine methosulfate (PMS), nicotinamide adenine dinucleotide hydride (NADH), and oxygen causing reduced NBT in Formazan. A volume of 0.5mL of sample was added to 0.5mL of a solution containing NADH (189 microM) and NBT (120 microM) with Tris-HCl (40mM, pH = 8). The reaction started after the addition of 0.5mL of PMS (60microM). Control sample was measured using only distilled water. After 5min of incubation, control absorbance was measured at 560 nm at room temperature.
The nitric oxide inhibitory activity was determined according Khayami et al method. A volume of 1mL of sodium nitroprusside 10nm was added to 250microL de phosphate buffered saline (PBS) and 250microL of test solution and it was shaken. The previous solution was incubated for 150 min at 25ºC and following add 3mL of sulfanilic acid and 0.33% of acetic acid glacial. After 5 min at room temperature, it was add 3mL of n-(1-naphthyl)ethylenediamine dihydrochloride (NED, 0.1% m/v) and incubated for 30 min at 25ºC. The absorbance was measured at 533nm. The previous procedure was employed to control obtained using water.
The free radical 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) was obtained by ABTS oxidation with potassium persulfate 140mM for 12h in dark, according Zulueta et al method. It was prepared a solution with 10mL ABTS 7nm and 176microL persulfate and storage at room temperature by 12h in dark. The previous solution was diluted with ethanol until 0.7 absorbance at 734nm. A volume of 2850microL of ABTS radical was added to 150microL of sample and to 150microL of water. After 30min in dark the absorbance was determined at 734nm. The Trolox concentration was using as standard (mM Trolox/L). This test was performed for several extract concentrations in order to calculate IC50.
Data statistical analysis was performed using SPSS Statistics (Statistical Package for Social Sciences) (version 22) software. Mean and standard error of the mean were used. Shapiro-Wilk and Repeated Measures ANOVA of mixed type were used. Independent samples T-test was used to assess the difference between the 2 groups for total caloric value, carbohydrates, protein and lipid ingested, Cmax (maximum concentration), ΔCmax (variation of maximum concentration), and AUC (area under the curve) Incremental values. The AUC was calculated by Software GraphPad Prim (version 7.03). All statistical tests were performed at the 5% level of significance.
- Conditions
- Hyperglycemia, Postprandial
- Being tested
- Placebo OGGT, Ginger aqueous extract
- Keywords
- Ginger, hyperglycemia, antioxidant, phenols, flavonoids
- Medical subject headings
- Hyperglycemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo OGGTOther
After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.
Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
Ginger aqueous extractOther
After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.
Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
| Study group | Role | What they receive |
|---|---|---|
| Placebo (OGTT) | Placebo comparator | The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Receives: Other: Placebo OGGT |
| Intervention (OGTT plus Ginger extract) | Experimental | The intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose). Receives: Other: Ginger aqueous extract |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial blood glucose levels time curve
Mean blood glucose levels (mmol/L) obtained after oral glucose tolerance test in control group and after oral glucose tolerance test plus baobab extract in intervention group at different moments
Measured: up to 120 minutes after intervention
Incremental area under the curve of glucose levels
the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0).
Measured: At 120 minutes after intervention
Blood glucose maximum concentrations
Mean blood glucose levels (mmol/L)
Measured: At 60 minutos after intervention
Antioxidant activity determination of Ginger extract
Mean values of anion and radical inhibition capacity and mean values of antioxidant capacity by ABTS (micromol TE/g)
Measured: At baseline
Total phenolic compounds
Mean values of total phenolic compounds (mg of gallic acid/g ginger)
Measured: At baseline
Flavonoids
Mean values of flavonoids (mg quercetin of/g ginger)
Measured: At baseline
Secondary outcomes (3)
Weight of participants
Mean values of weight (in kilograms)
Measured: At baseline
Body mass index of participants
Mean values of body mass index (Kg/m2), calculated as weight (Kg) divided by height (m2) squared (Kg/m2)
Measured: At baseline
Height of participants
Mean values of height (in meters)
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2021
- Study start5 May 2017
- Primary completion30 Jul 2017
- Study completion30 Oct 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hyperglycemia, PostprandialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRL
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Maria Fernanda Mesquita, Principal investigator, Centro de Investigação Interdisciplinar Egas Moniz, Instituto Universitário Egas Moniz, Portugal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05152745
- Sponsor's protocol ID
- 519ginger
- Status last verified
- Nov 2021
- First submitted
- 29 Nov 2021
- Last updated
- 10 Dec 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ginger Extract on Postprandial Glycemia of Healthy Adults and Its Antioxidant Properties: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05152745
- Acronym / sponsor ID
- 519ginger
- Conditions
- Hyperglycemia, Postprandial
- Keywords
- Ginger, hyperglycemia, antioxidant, phenols, flavonoids
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Egas Moniz - Cooperativa de Ensino Superior, CRLUniversity, hospital or other
- Study start
- 5 May 2017 (actual)
- Primary completion
- 30 Jul 2017 (actual)
- Study completion
- 30 Oct 2017 (actual)
- First posted
- 10 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Hyperglycemia is a risk factor to disease development, namely, diabetes mellitus. The blood glucose level management, particularly on post-prandial period has an important role in the prevention of different diseases. Ginger is a specie that has been demonstrated a benefit effect on glycaemia on diabetes.
Aim: The aim of this study was 1) to investigate the effects of ginger infusion in the glycaemic response in nondiabetic adults; 2) to evaluate total phenolic content the antioxidant activity of Ginger (Zingiber officinale Roscoe) aqueous extracts.
Methodology: 24 nondiabetic subjects were randomly allocated into two groups: intervention group (GI; n=15) and control group (GC; n=15). An oral glucose solution (OGTT) and an OGTT following ginger extract solution were administrated in control and intervention groups, respectively. Blood glucose levels were measurement at fasting and after 30, 60, 90 and 120 minutes after interventions in both groups. Total phenolic content and flavonoids compounds determination of the aqueous ginger extract was determined according to Prabha method. Antioxidant activity was also measured through ABTS method and free radicals inhibition capacity. Repeated Measures ANOVA of mixed type and independent samples t-test were used in statistical analysis.
Detailed description
This clinical trial was approved by Ethical Committee (process number 519 at 23 November 2016). All participants signed a written informed consent after aim and experimental risk procedures explanation and its protected confidentiality was guaranteed. The experimental procedure involving human was care out according Declaration of Helsinki.
This blind (to participants) randomized controlled clinical trial was conducted at Egas Moniz higher education school in 30 nondiabetic adults. Participants with ages between 18 and 40 were selected and randomly allocated in intervention group (IG) (n=15) and control group (CG) (n=15), in which participants were alternated include in the groups. The IG performed an oral glucose tolerance test (OGTT) followed by aqueous ginger extract administration and the CG performed an OGTT administration alone.
For ginger extract preparation, powder ginger (Zingibre officinalle Roscoe) was obtained from Portugal Company with India origin and stored in a dried environmental locally until needed. The product has a batch number of LI1GIGRNT150012. Powder ginger was individually weight (0.2g each dose) and added to 100mL of boiled water obtaining the ginger extract, infusing 10 minutes. Ginger extract solution was after cooled at room temperature and distributed to each participant. This method was adapted by Wilkinson, J. M. (2000). For chemical analysis, a aqueous ginger extract previously obtained was used.
Regarding to blood glucose level assessment, the blood sample were collected for each participant using a capillary drop blood before the intervention (fasting) and after 30, 60, 90 and 120 minutes. The blood glucose level analysis was performed using a strips for glucose meter (Onetouch Select Plus Flex), a sterilized lancet and a glucose meter equipment.
General characteristics data of the participants were collected, namely, anthropometrics data, pharmacologic treatment and medical condition using a questionnaire. In addition, a 24-hour dietary recall at the day before the intervention was employing to sample participants. The nutritional analyzed of diet ingested was performed by Food Processor SQL (version 10.5.0).
The total phenolic compounds determination of the aqueous ginger extract was determined according to Folin-Ciocalteu method. The total phenolic results were expressed as mg gallic acid equivalent (GAE)/L of ginger extract. A volume of 125 μL of ginger extract and 2 mL of sodium carbonate were added to 2.5 mL of Folin-Ciocalteu reagent. After 15 min the absorbance was measured at 765 nm. The flavonoids compounds determination of the aqueous ginger extract was determined according to Prabha method. The flavonoids results were expressed as mg quercetin equivalent (GAE)/L of ginger extract. A volume of 2 mL of ginger extract were added to 0.1 mL of aluminum chloride anhydrous solution (10%), 0.1 mL of potassium acetate (1M) and 2.8 mL of distilled water. After 30 min the absorbance was measured at 415 nm.
The antioxidant activity was measured through different assays:
The superoxide anion radicals scavenging activity was determined based on Morais et al method. Superoxide anion was generated by reacting phenazine methosulfate (PMS), nicotinamide adenine dinucleotide hydride (NADH), and oxygen causing reduced NBT in Formazan. A volume of 0.5mL of sample was added to 0.5mL of a solution containing NADH (189 microM) and NBT (120 microM) with Tris-HCl (40mM, pH = 8). The reaction started after the addition of 0.5mL of PMS (60microM). Control sample was measured using only distilled water. After 5min of incubation, control absorbance was measured at 560 nm at room temperature.
The nitric oxide inhibitory activity was determined according Khayami et al method. A volume of 1mL of sodium nitroprusside 10nm was added to 250microL de phosphate buffered saline (PBS) and 250microL of test solution and it was shaken. The previous solution was incubated for 150 min at 25ºC and following add 3mL of sulfanilic acid and 0.33% of acetic acid glacial. After 5 min at room temperature, it was add 3mL of n-(1-naphthyl)ethylenediamine dihydrochloride (NED, 0.1% m/v) and incubated for 30 min at 25ºC. The absorbance was measured at 533nm. The previous procedure was employed to control obtained using water.
The free radical 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) was obtained by ABTS oxidation with potassium persulfate 140mM for 12h in dark, according Zulueta et al method. It was prepared a solution with 10mL ABTS 7nm and 176microL persulfate and storage at room temperature by 12h in dark. The previous solution was diluted with ethanol until 0.7 absorbance at 734nm. A volume of 2850microL of ABTS radical was added to 150microL of sample and to 150microL of water. After 30min in dark the absorbance was determined at 734nm. The Trolox concentration was using as standard (mM Trolox/L). This test was performed for several extract concentrations in order to calculate IC50.
Data statistical analysis was performed using SPSS Statistics (Statistical Package for Social Sciences) (version 22) software. Mean and standard error of the mean were used. Shapiro-Wilk and Repeated Measures ANOVA of mixed type were used. Independent samples T-test was used to assess the difference between the 2 groups for total caloric value, carbohydrates, protein and lipid ingested, Cmax (maximum concentration), ΔCmax (variation of maximum concentration), and AUC (area under the curve) Incremental values. The AUC was calculated by Software GraphPad Prim (version 7.03). All statistical tests were performed at the 5% level of significance.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo (OGTT) | Placebo comparator | Other: Placebo OGGTThe control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. |
| Intervention (OGTT plus Ginger extract) | Experimental | Other: Ginger aqueous extractThe intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose). |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- subjects without glucose metabolism alteration
Key exclusion criteria (5 listed)
- medication for glycemia
- had gastrointestinal symptoms or disease
- pregnancy or lactation
- had allergy to ginger.
- to ingest ginger at the day before the intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo OGGTAfter overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis. | Other | Placebo (OGTT) |
| Ginger aqueous extractAfter overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis. | Other | Intervention (OGTT plus Ginger extract) |
Primary outcome
Postprandial blood glucose levels time curve
Time frame: up to 120 minutes after intervention
Mean blood glucose levels (mmol/L) obtained after oral glucose tolerance test in control group and after oral glucose tolerance test plus baobab extract in intervention group at different moments
Incremental area under the curve of glucose levels
Time frame: At 120 minutes after intervention
the blood glucose incremental area under the curve (AUCi) of each participant was defined using the GraphPad Prism program (version 5.0).
Blood glucose maximum concentrations
Time frame: At 60 minutos after intervention
Mean blood glucose levels (mmol/L)
Antioxidant activity determination of Ginger extract
Time frame: At baseline
Mean values of anion and radical inhibition capacity and mean values of antioxidant capacity by ABTS (micromol TE/g)
Total phenolic compounds
Time frame: At baseline
Mean values of total phenolic compounds (mg of gallic acid/g ginger)
Flavonoids
Time frame: At baseline
Mean values of flavonoids (mg quercetin of/g ginger)
3 secondary outcomes
Weight of participants
Time frame: At baseline
Body mass index of participants
Time frame: At baseline
Height of participants
Time frame: At baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2021.
Related trials for Hyperglycemia, Postprandial
Active, not recruiting
How Fig Polyphenols Affect Blood Sugar and Insulin Levels After Eating in Adults at Risk for Diabetes
Pre Diabetic
Enrolling by invitation
Development of Anti-Diabetic Nutraceuticals From Legume Seed Coats
Postprandial Hyperglycemia, Type 2 Diabetes
Active, not recruiting
Effect of a Sugar Replacement on Blood Glucose Levels in Healthy Adults
Postprandial Hyperglycemia, Hyperinsulinemia
Recruiting
Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring
Postprandial Glucose, Glucose Levels
Not yet recruiting
Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism
Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria Fernanda Mesquita principal investigator
Centro de Investigação Interdisciplinar Egas Moniz, Instituto Universitário Egas Moniz, Portugal
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ginger aqueous extract in people with Hyperglycemia, Postprandial, run by Egas Moniz - Cooperativa de Ensino Superior, CRL at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial blood glucose levels time curve (time frame: up to 120 minutes after intervention). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2021.